Meanwhile, F-circEA specifically elevates in EML4-ALK fusion gene positive NSCLC patients' plasma, thus monitoring the EML4-ALK translocation and guiding the EML4-ALK-targeted NSCLC therapy. The gene discussed is EML4; the disease is non-small cell lung carcinoma.